Peer-reviewed veterinary case report
Robenacoxib doses tested for dog knee joint pain from urate crystals
By Borer, L R et al.·Published in Journal of veterinary pharmacology and therapeutics·2017·Elanco Animal Health Research Centre·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs.
- Species:
- dog
Plain-English summary
Twelve beagle dogs with painful swelling in their knee joints due to urate crystals were given different doses of robenacoxib, a medication that helps reduce pain and inflammation. The dogs showed improvement in how much weight they could put on their legs and experienced less pain and swelling with doses between 0.5 and 2 mg/kg. Higher doses did not provide additional benefits. Robenacoxib worked faster than another common pain medication, meloxicam, making it a good option for quick relief. Overall, robenacoxib was effective in helping these dogs feel better.
People also search for: dog knee pain treatment · robenacoxib for dogs · beagle joint swelling relief
Abstract
The objective of the study was to establish the dose-response relationship for robenacoxib, a selective cyclooxygenase (COX)-2 inhibitor, in a urate crystal model of acute synovitis. In a randomized partial Latin square design trial, 12 beagle dogs were administered orally single doses of robenacoxib (0.5, 1, 2, 4 and 8 mg/kg), placebo and the positive control meloxicam (0.1 mg/kg), 3 h after injection of sodium urate crystals into a stifle joint. Dogs were assessed for weight bearing on a force plate and by subjective clinical orthopaedic observations. Robenacoxib produced dose-dependent improvement in weight bearing, and decreased pain on palpation and joint swelling, over the dose range 0.5-2 mg/kg with no further increase in effect over the range 2-8 mg/kg. For weight bearing on the force plate, the EDof robenacoxib was 0.6-0.8 mg/kg. The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h). Robenacoxib significantly inhibited COX-2 at all doses, with dose-related activity. Robenacoxib did not inhibit COX-1 over the dose range 0.5-4 mg/kg, but produced transient inhibition at 8 mg/kg. In conclusion, oral administration of robenacoxib over the dose range 0.5-8 mg/kg demonstrated significant analgesic and anti-inflammatory efficacy in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27493016/